Translational Relevance
Gene signatures that predict survival in NSCLC patients have been developed to identify patients with high risk of recurrence after radical resection and to personalize additional treatment options. However, the clinical value of multi-gene signatures is controversial, as they rarely outperform prognostication using conventional parameters. Also, the adaptation of multiplex mRNA-based assays to formalin-fixed paraffin-embedded tissue samples for clinical diagnostics remains a challenge. Instead, this study focused on the identification of single genes as prognostic biomarkers. A discovery screening was performed in a novel wellcharacterized NSCLC cohort and candidate genes were confirmed in a meta-analysis of publicly available data sets. The presented genes demonstrated prognostic impact and can be investigated further as promising biomarkers as well as targets for functional studies and drug development. Indeed, the potential application in routine diagnostics for one of these genes, CADM1, was verified by immunohistochemistry in two large tissue microarray cohorts of archived FFPE tissue samples.
INTRODUCTION
Lung cancer is the leading cause of cancer-related death worldwide [1] . Even in early stage patients treated by surgery the risk of recurrence is high [2] and major efforts have been made to identify molecular markers that predict prognosis and response to additional therapy [3] .
Microarray-based gene expression profiling has successfully been used in clinical cancer research to sub-classify cancer entities, to predict prognosis or response to therapy, and to identify underlying mechanisms of tumor development [4] . In breast and colorectal cancer, prognostic gene expression signatures have been validated in independent patient cohorts and are now tested in prospective randomized clinical trials [5] [6] .
Several prognostic gene expression signatures have been published in non-small cell lung cancer (NSCLC) [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . However, a recent review critically evaluated the suggested signatures and concluded that in general they do not provide additional prognostic information compared to traditional clinical parameters [18] . Some prognostic multi-gene signatures have been confirmed in independent data sets [14] [15] [16] , but the impact of individual genes has rarely been assessed. Surprisingly, there is virtually no overlap between hitherto published gene signatures. An explanation might be that effects of single genes with broad confidence intervals are difficult to confirm using a sequential validation strategy, i.e. when genes identified as significant in one study are tested for significance in separate subsequent studies of comparably small sample size [19] .
Rather than to find new gene signatures, the aim of this study was to evaluate the expression levels of single genes for prognostic relevance. To this end, we generated gene expression array data from a large well-characterized single-institute cohort of operated NSCLC patients with complete clinical base-line information and long-term survival follow-up. We then sought to validate candidate genes in independent NSCLC data sets by the use of a metaanalysis approach, where the statistical significance associated with single genes is first assessed in each study separately. The significance across all studies is then calculated, combining the statistical power of multiple limited patient cohorts. As a proof-of-concept, our final goal was to test if the prognostic impact of mRNA transcript levels were translated into protein expression differences that could be assessed as biomarkers by immunohistochemistry in routine clinical diagnostics.
METHODS

Patients and tissue samples
The source population consisted of surgically treated primary NSCLC patients, reported to the Uppsala-Örebro Regional Lung Cancer Registry consecutively from 1995 through 2005, with available fresh-frozen tissue in the Uppsala Biobank at the Department of Pathology. The Regional Lung Cancer Registry is a clinical audit and research database that prospectively compiles information such as diagnostic procedure, histology, stage, performance status according to WHO, smoking history, and survival for all diagnosed lung cancer patients in the Uppsala-Örebro Region. The study was performed in accordance with the Swedish Biobank Legislation and Ethical Review Act (Uppsala regional ethical review board, reference #2006/325 and Linköping regional ethical review board, reference #2010⁄44-31).
All fresh-frozen tissue samples were collected using the same standardized protocol [20] [21] [22] [23] and each frozen section was reviewed by a pathologist (PM and JB) to confirm that the sample contained representative tumor tissue. Study inclusion was based on: i) NSCLC histology of squamous cell carcinoma, adenocarcinoma, or large cell carcinoma (including variants and NSCLC not otherwise specified), ii) tumor sample size >5 mm, iii) fraction of tumor cells ≥50%, iv) follow-up time of more than five years, and v) RNA integrity value (RIN) >7.0. If needed, tissue blocks were manually trimmed to enrich for tumor cells. Patients with a history of other cancers, or who had received neo-adjuvant chemotherapy, were excluded. In total, 196 tissue samples met the inclusion criteria. All investigators involved in the study, apart from the study statistician, were blinded to patient outcome throughout all laboratory analyses. Gene copy number data from 100 of these patients, and global gene expression data from 78 patients, have been described previously (GEO accession number GSE28582) [24] . In addition, gene expression data from the study cohort (n=196) was used to verify the prognostic impact of immunoglobulin kappa C [25] .
RNA extraction and microarray analysis
Five to ten sections (10µm) were cut from each frozen tissue block and collected into a tube with Buffer RLT (Qiagen, Hilden, Germany). Total RNA was extracted using the RNeasy Mini Kit following instructions from the manufacturer (Qiagen). RNA concentrations were measured with a ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA.), and the quality (RNA Integrity Number, RIN) was assessed using the Agilent 2100 6 Bioanalyzer system (Agilent Biotechnologies, Palo Alto, CA, USA). For each sample, 2µg of total RNA from each sample was used to prepare biotinylated fragmented cRNA for analysis on Affymetrix Human Genome U133 plus 2.0 arrays (54675 probe sets, Affymetrix Inc., Santa Clara, CA, USA). Sample preparation, processing and hybridization were performed according to the GeneChip® Expression Analysis Technical Manual (Affymetrix Inc., Rev. 5). The arrays were washed and stained using a Fluidics Station 450 and finally scanned using a GeneChip® Scanner 3000 7G. The subsequent analysis was carried out using the freely available statistical computing language R version 2.12.1 (http://www.r-project.org), including the R package meta for meta-analyses. The raw data (obtained as CEL files) was normalized using the robust multi-array average (RMA) method [26] . The complete microarray data set has been deposited in the Gene Expression Omnibus database (GSE37745).
Gene expression data analysis
Survival rates were calculated according to the Kaplan-Meier method. Overall survival (OS) was computed from the date of diagnosis to the date of death. Recurrence-free survival was computed from the date of diagnosis to the date of the last follow-up. Survival functions were compared with the log-rank test. Multivariate Cox survival analyses were performed with inclusion of the most important clinical parameters. Categorization was performed as follows:
age: <70 versus ≥70 years; patient performance status 0 versus I-III, tumor stage I versus II-IV. In addition to clinical data collected by the regional lung cancer registry, a review of patient records provided information regarding recurrence-free survival for a subset of 153 patients, while data on adjuvant treatment could be reliably established for 156 patients.
For the meta-analysis, five publicly available gene expression data sets that used the Affymetrix gene chip U133 or U133 plus 2.0 arrays were included (Shedden et squamous cell carcinomas, and 28 large cell carcinomas or NSCLC not otherwise specified), with 22277 probe sets overlapping between the arrays. The meta-analyses were conducted using the R package "meta" (http://CRAN.R-project.org/package=meta) with fixed effect models and random effects models based on parameter estimates of log hazard ratios in Cox models and their standard errors. For combining single estimates into one pooled estimate inverse variance weighting was used. Significance of the overall effect was measured with the p-value of the fixed effect models. Results were visualized with forest plots, also called confidence interval plots, where parameter estimates of all single studies and the pooled estimates along with their confidence intervals are plotted on top of each other. Adjustment for multiple testing was performed with the method of Benjamini and Hochberg (FDR; false discovery rate) [32] . All p-values were two-sided. Where no correction for multiple testing is indicated, the p-values were considered as descriptive measures. The CADM1 metagene was constructed as previously described [33] . All analyses were performed using R version 2.12.1.
Tissue microarray construction
The protein expression level of cell adhesion molecule 1 (CADM1) was analyzed in two independent cohorts using tissue microarrays (TMA) constructed from of formalin-fixed paraffin-embedded tumor tissue. Haematoxylin-eosin stained sections from all tissue blocks were reviewed by a pathologist in order to confirm the reported histological subtype and to 
RESULTS
Baseline characteristics of the Uppsala cohort
Gene expression microarray analysis was performed on RNA prepared from 196 fresh-frozen NSCLC samples that matched the pre-defined histologic and RNA quality criteria. Clinical data and overall survival was retrieved from the regional cancer registry, with follow-up times in the range of 5-15 years (Suppl. Figure 1a , Table 1 Unsupervised hierarchical cluster analysis of the gene expression array data revealed that tumor histology is the prominent denominator for the global mRNA transcript profile of NSCLC. Two main groups contained most of the adenocarcinomas and squamous cell carcinomas, respectively, based on clustering of all probe sets as well as on the 1000 probe sets with the lowest signal to noise ratio ( Figure 1 ). The large cell carcinoma/NSCLC not otherwise specified (NOS) cases were scattered within the two main clusters. Gene expression: univariate survival analysis in the Uppsala data set A Cox regression model was applied to identify genes with prognostic relevance. When all probe sets (n=54675) in the total cohort of 196 cases were analyzed, no gene showed a significant prognostic impact after adjustment for multiple testing with a false discovery rate (FDR) below 0.05. This was also true for the squamous cell cancer subgroup (n=66). In adenocarcinoma (n=106), only two annotated genes (SSR4 and FAM46C) were identified to be associated with survival with strictly adjusted p-values. Neither SSR4 nor FAM46C has yet been described as prognostic markers in NSCLC. FAM46C has been suggested to be involved in the regulation of protein translation, but its exact function is unknown [36] . Signal sequence receptor delta (SSR4) encodes one subunit of the translocon-associated protein complex involved in the transport of proteins across the endoplasmic reticulum membrane [37] .
Validation of candidate genes in a meta-analysis of NSCLC data sets
The workflow of the analysis is illustrated in Figure 2 . As rigorous adjustment for multiple testing may exclude relevant genes, we tested the 450 probe sets with an unadjusted significance level of p<0.01 (Uppsala cohort, all NSCLC, n=196, Suppl. Table 3a) in a metaanalysis of five available gene expression data sets generated on the Affymetrix platform, including in total 860 patients [26] [27] [28] [29] [30] . Of the 450 analyzed probe sets, 62 were significantly associated with survival in the meta-analysis (unadjusted p<0.01) and 17 thereof remained significant after adjustment for multiple testing (FDR<1%), i.e. it is likely that all 17 probes sets, representing 14 genes (Table 2a) , have a true prognostic impact.
The same strategy was applied on adenocarcinomas and squamous cell carcinomas separately.
In the Uppsala adenocarcinoma data set, 658 probe sets demonstrated an unadjusted significance level of p<0.01 (Suppl . Table 3b ). Of these, 56 probe sets were also significant in the meta-analysis (unadjusted p<0.01). Finally, six probe sets, corresponding to four genes, were confirmed with a FDR<1% (Table 2b ). In squamous cell carcinoma only 122 probe sets were associated with survival in the Uppsala cohort (unadjusted p<0.01), and the metaanalysis confirmed two probe sets (unadjusted p<0.01), none of which could be confirmed with a FDR<1% (Suppl. Table 3c ).
Performance of candidate genes in the Uppsala NSCLC cohort
To illustrate the prognostic impact of each probe set in the Uppsala cohort we performed a Kaplan-Meier analysis with samples dichotomized into two groups with expression levels ≤ Table 4 ). All identified genes exhibited an independent prognostic association with survival.
Higher CADM1 gene expression is associated with longer survival
As three CADM1 probe sets were identified as strong prognostic markers in the Uppsala cohort and in the meta-analysis, we constructed a CADM1 metagene of these probe sets 0.68-0.98, p=0.028). In the Uppsala cohort, the CADM1 metagene showed 2-and 5-year survival rates of 58% and 32% for patients with CADM1 expression below the median and 76% and 52% for patients with CADM1 expression above the median, respectively.
For a subset of patients we were able to retrieve data with regard to recurrence-free survival and adjuvant chemotherapy. Longer recurrence-free survival showed a significant association with high CADM1 gene expression (Suppl. When untreated patients were analysed separately, high CADM1 gene expression was clearly associated with longer overall survival (n=71; HR=0.46, CI 0.26-0.81, p=0.007). For patients that had received adjuvant treatment, the prognostic impact was not significant (n=29; HR=0.67, CI 0.29-1.54, p=0.34) in NSCLC patients with available clinical information. As the combined CADM1 probe sets displayed prognostic information independent of known prognostic markers, with a risk reduction of 43% in the Uppsala cohort ( Table 5 ). The 2-year survival rate was 81% and for the high and 68% for the low expression group. The 5-year survival rates were 57% and 42% for patients with high and low CADM1 protein expression, respectively. Recurrence-free survival in patients with available clinical follow-up revealed a clear trend towards longer survival with CADM1 positive staining (n=150, HR=0.60, CI 0.34-1.06, p=0.076).
In concordance with the gene expression analysis, the impact of CADM1 was more pronounced when the analysis was restricted to the adenocarcinoma subtype (n=195, HR=0.52, CI 0.34-0.78, p=0.002, Figure 4b ) with 2-year and 5-year survival rates 86% and 64% for high protein expression. For low protein expression the 2-and 5-year survival rates were 70% and 40%, respectively. The association was not significant in the squamous cell carcinoma subtype (n=120, p=0.80). CADM1 was prognostic also when only stage I adenocarcinoma patients (n=133) were analyzed (Suppl. Figure 4 , HR=0.53, CI 0.33-0.88, p=0.013). The 2-year and 5-year survival rates for stage I adenocarcinoma patients with high CADM1 protein expression was 95% and 72% compared to 74% and 46% in the CADM1 low expression group, respectively. In stage II adenocarcinoma patients the log-rank test did not reach significance, most probably because of the small sample size of only 30 cases (p=0.14).
To further validate CADM1 staining as a diagnostic tool we stained and evaluated an independent NSCLC cohort including 262 patients. The staining was evaluable in 254 cases. HR=0.22, CI 0.05-0.94, p=0.042 ). In conclusion, we were able to translate our findings from the array analysis of mRNA levels to clinically applicable immunohistochemical protein levels.
DISCUSSION
We introduced a novel NSCLC gene expression data set with complete annotation of clinical parameters as well as long-term follow-up. The presented statistical approach was based on stringent criteria to evaluate the prognostic impact of single genes, and links our novel data set to multiple independent patient cohorts. This combined screening and meta-analysis strategy identified with high confidence 17 probe sets (14 genes) independent of histology, and 6 probe sets (4 genes) in the subgroup of adenocarcinoma, that were associated with survival. As a proof of concept, we selected CADM1 for further evaluation. The prognostic impact of CADM1 was verified on the protein level in two independent cohorts, comprising altogether 605 evaluable NSCLC cases.
CADM1 belongs to the immunoglobulin superfamily (IGSF) of adhesion molecules and is located on chromosome 11q23. It was isolated primarily as IGSF4 and has been shown to function as a tumor suppressor in lung cancer [40] ; hence also named tumor suppressor in lung cancer 1 (TSLC1). Indeed, loss of heterozygosity (LOH) was observed in around 40% of lung cancers [41] [42] and loss of expression was also associated with hypermethylation of the corresponding promoter region in 44% of human lung cancers. In a previous study including 93 NSCLC patients, loss of protein expression was associated with poor prognosis [43] . In our study we could confirm this result in two NSCLC cohorts using a novel polyclonal antibody. The staining intensity ranged from strong membranous staining to clear cut negative expression. These findings clearly support the clinical and biological relevance of CADM1 as a tumor suppressor in NSCLC. Additionally we showed that the prognostic relevance is retained in patients with stage I disease. Thus CADM1 is a candidate marker for the stratification of patients for adjuvant chemotherapy. Since we used immunohistochemistry on formalin-fixed paraffin-embedded tissue, a direct implementation in diagnostics is possible. Alongside CADM1 we present a list of additional candidate genes with a strong association with survival in NSCLC. Further studies are needed to characterize the functional and clinical importance of these genes. For instance, the glycoprotein CUB domain containing protein 1 (CDCP1) represents a potential drugable target. CDCP1 is a cell surface protein, which has been linked to the EGFR-, SRC-and AKT-pathways and regulates PARP1-induced apoptosis.
CDCP1 was described to be involved cancer migration and invasion, and inhibition effectively prevents tumor cell dissemination in animal models of prostate and lung cancer [44-46].
Previous studies have described prognostic gene expression signatures with varying discriminating prognostic power in independent data sets [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [27] [28] [29] [30] [31] . A clinical relevance of single genes included in these signatures has not yet been demonstrated, and assays dependent on fresh-frozen tissue are difficult to introduce into routine diagnostics [18] .
Recently a large scale study applied a quantitative PCR-based assay for formalin-fixed paraffin-embedded tissue, including eleven cancer-related genes and three reference genes, to predict outcome in operated non-squamous NSCLC patients [47] . The high-risk signature group showed 74%, the intermediate 57%, and the low risk group 45% 5-year survival rates in a validation cohort of 1006 Chinese patients. In order to evaluate this multi-gene signature in our cohort, we adjusted the expression values of the array data anticipating that they correlate with PCR data. As one gene (WNT3) was not represented on the Affymetrix array, the score is based on only ten cancer target genes. With these limitations in mind, we analyzed the risk score in the Uppsala cohort and in the meta-analysis. Indeed, we could recapitulate previous findings, indicating that this multi-gene signature is robust (Suppl. discussion). However, CADM1 gene expression and the immunohistochemical protein score displayed similar prognostic impact, indicating that comparable prognostic information can be obtained from single genes.
A strength of our study is that it is based on a large well-characterized NSCLC cohort, to our knowledge one of the largest single-institute microarray data sets. Complete clinical annotation allowed analysis of clinically relevant subgroups, e.g. stage I adenocarcinoma.
Noteworthy is the inclusion of patient performance status, a parameter not annotated in previous data sets. Histopathologic review, fresh-frozen tissue handling, selection of representative tissue with high tumor cell content, and mRNA extraction were performed using uniform and standardized protocols within the infrastructure of an established biobank and a diagnostic molecular pathology laboratory [20] [21] [22] [23] . Thus we believe that artifacts due to poor tissue quality and methodological inconsistencies have been minimized. Applying sequential validation strategies, biomarkers identified in one study enter iteratively as candidate markers to be confirmed in other data sets. As a consequence there is high confidence in the relevance of the final candidates. However, it has been demonstrated that this approach yields many false negative results [19] . Instead, we applied in this study a combined sequential and meta-analysis approach, where candidate biomarkers with prognostic relevance in the primary cohort were further evaluated in a meta-analysis of several publicly available data sets. This procedure allows reliable validation in a large collection of samples while combining several independent smaller data sets with wide confidence intervals for single gene effects.
In conclusion, utilizing a high quality NSCLC data set together with an innovative metaanalysis approach, we identified novel prognostic genes with high reliability. Based on tissue microarray analysis of archived tissues, we demonstrated the clinical relevance of CADM1 and a potential immunohistochemical application in molecular diagnostics. The estimate from each study is represented by a grey box, where the size of the box is proportional to the weight of the respective study in the meta-analysis. For each study a horizontal line indicates the corresponding 95% confidence interval. The plot is on a logarithmic scale so that the confidence intervals are symmetric. A solid vertical line marks the hazard ratio 1 (no effect). The result of the meta-analysis (fixed effect and random effects model) is represented by a diamond, the center of the diamond indicates the pooled estimate (also marked by vertical lines), the dimension the corresponding 95% confidence interval. 
